Introduction
Coagulation factor V (FV) is a critical protein in blood coagulation that circulates in the blood as a 330,000-MW monomer at a concentration of 7 g/ml (21 n M ) [1] . It has a regulatory role in both procoagulant and anticoagulant pathways. As a procoagulant, activated FV (FVa) is the nonenzymatic cofactor to activated factor X (FXa) in the activation of prothrombin to thrombin and enhances FXa proteolytic activity by several orders of magnitude. In the anticoagulant feedback loop, thrombin activates protein C in the thrombin-thrombomodulin complex to activated protein C (APC). Subsequently, APC inactivates procoagulant FVa and activated factor VIII (FVIIIa) by proteolysis, leaving them unable to act as cofactors to FXa and FIXa, respectively. Without their respective cofactors, FXa and FIXa are not significantly proteolytically active.
The known anticoagulant activity of FV consists of a cofactor function of FV for APC and protein S in the inactivation of the procoagulant FVIIIa [2, 3] . A cleavage of FV at R506 by APC is required for this cofactor function [4, 5] , which was discovered in the analysis of APC resistance in patients with a mutant form of FV known as FV Leiden . In this mutant, R506 is replaced by a Q, which renders the 506 position insensitive to proteolysis by APC (FV Leiden is hereafter referred to as Q506-FV). Therefore, Q506-FV does not display this anticoagulant activity [4, 6, 7] . The importance of the FV cofactor activity to APC was emphasized by Castoldi et al. [8] , who described that the APC resistance of Q506-FV was about 50% due to insensitivity of Q506-FVa to APC proteolysis and about 50% due to Q506-FV lacking APC cofactor activity for the inactivation of FVIIIa.
Apart from proteolysis by APC, FVIIIa is also inactivated by spontaneous dissociation of its A2 domain, which gives FVIIIa a half-life of approximately 2 min in plasma [9] . Because of this rapid loss of the A2 domain, it has been argued that this is the primary method by which FVIIIa is inactivated in vivo, suggesting APC-mediated inactivation to be of lesser physiological relevance [10, 11] . We therefore hypothesized that since Q506-FV is a known risk factor for thrombosis, FV is also an anticoagulant cofactor for APC in the inactivation of FVa.
APC cleaves FVa at positions R306, R506 and R679, of which the cleavage at R506 occurs the fastest and that at R679 the slowest [12] . Cleavage at R306 causes dissociation of the A2 domain from the FVa molecule, resulting in total loss of activity in the prothrombinase complex [12, 13] . Cleavage at R506, however, results in a partially active intermediate [12, 14] .
To test our hypothesis, we investigated FV anticoagulant activity in a plasma-based clotting assay that is sensitive to FV but insensitive to FVIII. FV clearly prolonged clotting time in the presence of APC, suggesting that the presence of FV enhanced FVa inactivation.
Materials and Methods
Protein S, human fibrinogen, FX, prothrombin and thrombin were from Enzyme Research Laboratories (South Bend, Ind., USA). APC and plasma-derived FV were from Haematologic Technologies (Essex Junction, Vt., USA); plasma-derived FV from Haematologic Technologies is referred to as plasma-derived wildtype (WT)-FV in this paper. Recombinant full-length FVIII was a gift from Bayer Corporation (Berkeley, Calif., USA). Bovine brain phosphatidylserine and bovine brain phosphatidylethanolamine were from Sigma (St. Louis, Mo., USA). Bovine liver phosphatidylcholine was from Avanti Polar Lipids (Alabaster, Ala., USA). Bovine serum albumin (BSA) was from Calbiochem/EMD Biosciences (La Jolla, Calif., USA). M662C/D1828C-FVIII was characterized previously [15, 16] . FV-deficient plasma was from Affinity Biologicals (Ancaster, Ont., Canada). FVIII-deficient plasma and normal pooled human plasma were from George King Biomedical Inc. (Overland Park, Kans., USA). Platelin LS activated partial thromboplastin time (APTT) reagent was from Trinity Biotech LPC (Bray, Wicklow, Ireland). FVIII-specific human IgG monoclonal antibody BO2C11 [17] was a generous gift from Dr. Marc Jacquemin (University of Leuven, Leuven, Belgium). The chromogenic substrate H-D -cyclohexylglycine-AlaArg-paranitroanilide (Pefachrome TH) was from Centerchem Inc. (Norwalk, Conn., USA). Benzamidine and D -Phe-Pro-Arg chloromethyl ketone were from Calbiochem. Phenylmethanesulfonyl fluoride was from Sigma.
Phospholipid Vesicles
Phospholipid vesicles composed of 40% phosphatidylcholine, 20% phosphatidylserine and 40% phosphatidylethanolamine (M/M/M) (PCPSPE) were prepared as described previously [18] .
Recombinant FV Mutant Preparations
Ser2183Ala B domain-deleted FV was produced as described elsewhere [13] . In this FV variant, the segment 812-1491 of the B domain is absent, and it will be referred to as WT-FV throughout this paper. Site-directed mutagenesis was used to generate the R506Q mutant of this FV. The cDNAs for these FV variants were inserted into the expression vector pED [19] and transfected into modified BHK cells (a kind gift from Dr. Rodney Camire, Philadelphia, Pa., USA) together with the plasmid pRSVneo for selection with ge neticin. FV was purified from conditioned medium via precipi tation with 16% polyethylene glycol 6000, followed by binding to an anti-FV light chain monoclonal antibody column (AHV5101-Sepharose, AHV5101 from Haematologic Technologies) as described elsewhere [13, 20] .
Dilute Prothrombin Time Clotting Assay
All clotting assays were performed with a STart 4 semiautomated hemostasis analyzer from Diagnostica Stago (Parsippany, N.J., USA). Plasma was diluted 5 ! in HBS-0.5% BSA (pH 7.4) and supplemented with 1 mg/ml human fibrinogen and 75 M PCPSPE (40: 20: 40) phospholipid vesicles. Either FV or FVIII was then added to the plasma mix, after which APC or HBS-0.5% BSA was added and the mix was kept at 37 ° C for 3 min. Clotting was initiated by Dade Innovin (Siemens Healthcare Diagnostics Inc., Deerfield, Ill., USA) diluted in recalcification buffer (HBS, 0.5% BSA, 12.5 m M CaCl 2 , pH 7.4). The final reaction volume was 150 l, and final concentrations were as follows: 15 ! diluted plasma, 25 M PCPSPE phospholipid vesicles, 0.33 mg/ml human fibrinogen, 4.5 n M APC, 180 ! diluted Innovin and approximately 4 m M free Ca 2+ . Other reagents were at the concentrations indicated in the text.
APTT Assay
A volume of 50 l of plasma was mixed with 50 l of Platelin LS APTT reagent and incubated at 37 ° C for 3 min. Clotting was initiated by addition of 50 l of recalcification buffer (HBS-0.5% BSA-25 m M CaCl 2 , pH 7.4).
Results
To investigate a possible FV cofactor effect in FVa inactivation by APC, we designed a clotting assay that was sensitive to FV but was insensitive to FVIII (a dilute pro- thrombin time clotting assay). FV was titrated at final concentrations from 0 to 18 n M into this assay using FVdeficient plasma, and clotting time was measured in the absence or the presence of 4.5 n M APC. We used this assay to monitor APC activity with an APC sensitivity ratio (APCsr), which was calculated by dividing clotting time in the presence of APC by clotting time in the absence of APC. An increase in APCsr indicates an increase in APC anticoagulant activity, and a ratio of 1.0 indicates no APC anticoagulant activity. Titrations of WT-FV revealed an increase in clotting time in the presence of APC as the FV concentration increased ( fig. 1 a) , indicating an increase in APC activity. However, as mentioned above, clotting times plateaued at 35 s in the absence of APC. Therefore, the APCsr increased as the FV concentration increased, from a ratio of 1.7 when no FV was added to 3.3 at 18 n M FV ( fig. 1 b) . These experiments were performed with B domain-deleted FV [13] in order to enable direct comparison between WT and recombinant mutant Q506-FV, but similar results were obtained using plasma-derived WT-FV (data not shown). Thorelli et al. [21] already confirmed that a similar B domain-deleted FV variant was capable of APC cofactor activity during FVIIIa inactivation. In addition, since the plasma and therefore the protein S are diluted in this assay, we also performed this FV titration in the presence of 40 n M additional protein S. The results were essentially the same (data not shown). These data suggest that FV functioned as an anticoagulant cofactor to APC during the inactivation of FVa.
Mutation of FV at R506 to Q abolishes APC cofactor activity for FVIIIa inactivation since APC cleavage at R506 in FV is required for APC cofactor activity [4] . Unlike WT-FV, Q506-FV did not cause an increase in clotting time at higher FV concentrations in the presence of APC ( fig. 1 c) . This resulted in an APCsr of approximately 1 over the whole concentration range of Q506-FV. Therefore, as was the case for FVIIIa inactivation, Q506-FV did not show cofactor activity for APC in the inactivation of FVa.
In order to confirm that procoagulant FVa was present in these clotting assays with FV titrations, these assays were also performed in the presence of 2 n M WT-FVa. This concentration of FVa gave a clotting time of approximately 40 s in the absence of any added FV. Addition of the lowest concentration of WT or Q506-FV decreased the clotting time by only a few seconds further, and higher concentrations of FV had no further effect in the absence of APC ( fig. 2 ). WT-FV or Q506-FV were titrated up to 6 n M , and, as before, an increase in WT-FV caused an increase in clotting time in the presence of APC, with the APCsr ranging from 2 to 2.6. Increasing concentrations of Q506-FV had no impact on clotting time, thus generating an APCsr of 1 throughout the concentration range. These data demonstrated that FVa was present in the assays in figure 1 , and that in the presence of FVa, WT-FV still showed an anticoagulant effect when APC was present.
Because FV is a cofactor for APC in the inactivation of FVIIIa, we performed a variety of controls to confirm that the dilute prothrombin time clotting assay was not sensitive to FVIII or to FVIIIa inactivation. The FVIIIspecific human IgG monoclonal antibody BO2C11 [17] was used to block FVIII procoagulant activity. Normal plasma was incubated with BO2C11 and then assayed in the dilute prothrombin time clotting assay or in a standard APTT assay. In the latter, the antibody prolonged clotting time approximately 2-fold, whereas BO2C11 had no effect on the dilute prothrombin time clotting assay ( fig. 3 a) . The FVIII-inhibitory function of BO2C11 was confirmed with purified proteins in a factor Xase assay (data not shown).
BO2C11 was then used to block FVIII activity in a repeat of the FV titrations as performed in figure 1 . BO2C11 had no effect on the clotting times or on the APCsr ( fig. 3 b) . Additionally, FVIII-deficient plasma had a normal clotting time in the dilute prothrombin time assay ( fig. 3 c, no APC zero point), and titrating FVIII into FVIII-deficient plasma had no effect on this clotting time either in the absence or the presence of APC, even though APC did prolong the clotting time to 1 80 s ( fig. 3 c) . This experiment was also performed with fulllength WT-FVIII and in the presence of the BO2C11 antibody, neither of which had any effect on clotting time in FVIII-deficient plasma (data not shown). Controls using normal human plasma in the dilute prothrombin time clotting assay and the APTT assay showed that the amount of time that BO2C11 was preincubated with the plasma did not itself influence the clotting times (data not shown). However, as shown, this assay was very sensitive to FV, and clotting times were greatly prolonged in the absence of any FV ( fig. 1 , 2 ) . At these greatly prolonged clotting times in FV-deficient plasma, a small procoagulant effect was observed at extremely high FVIII concentrations. Clotting time ranged from 160 s when no FVIII was added to 140 s at 8 U/ml FVIII ( fig. 3 d) . This effect was more pronounced in the presence of APC, with clotting times ranging from 290 s when no FVIII was added to 190 s at 8 U/ml FVIII. This indicates that this assay is somewhat sensitive to FVIII only in the complete absence of FV when clotting times are greatly prolonged. From the data presented in figure 3 , we concluded that the dilute prothrombin time clotting assay was not sensitive to FVIII under our experimental conditions.
Discussion
In this study, we have shown an anticoagulant effect of FV as a cofactor for APC as measured in a clotting assay sensitive to FV activity. We have excluded that this assay was sensitive to FVIII. An inhibitory monoclonal antibody directed against FVIII (BO2C11) did not affect the clotting time in the FV titrations in FV-deficient plas- [8] previously illustrated the importance of FV cofactor activity for APC in the inactivation of FVIIIa, using plasma-based assays that were sensitive to either both FVa and FVIIIa or FVIIIa alone. In this earlier study, an anticoagulant effect of FV was also shown in thrombin generation assays, under conditions where both FVIIIa and FVa activity were measured. It was assumed, however, that only FVIIIa inactivation by APC/ protein S was enhanced by FV and not FVa inactivation. In the present study, we isolated FVa activity and observed that FV did enhance FVa inactivation. Thus, our results complement and extend the findings of Castoldi et al. [8] and suggest that the anticoagulant effect of FV on FVa inactivation may have also played a role in their study.
The effect of FV on FVa inactivation suggests a role for FV as an anticoagulant in normal homeostasis. One purpose of this effect of FV on FVa inactivation may be to prevent blood from reaching a clotting threshold by enhancing the inactivation of trace FVa that is formed while the FV concentration is high. Furthermore, FV may help APC localize and limit clot formation since, under flow, fresh blood with normal levels of FV would flow over the site of active coagulation.
Inactivation of FVIIIa by APC takes place via cleavages at R336 and R562. The latter is the slower cleavage and is required for full inactivation of the FVIIIa molecule. Our lab has recently shown that FV enhanced cleavage at both R336 and R562 in FVIIIa, but cleavage at R562 was enhanced to a greater extent than cleavage at R336 [22] . It is therefore possible that FV as cofactor for APC will show a similar pattern in the inactivation of FVa, namely a greater stimulation of R306 cleavage than R506 cleavage. In support of this, the APCsr dropped to 1 in the Q506-FV titrations ( fig. 1 , 2 ) , which suggests that Q506-FVa was not significantly inactivated by APC. This could result from reduced cleavage at R306 in Q506-FVa when the FV cofactor function is absent. However, further studies will be required to elucidate which cleavage in FVa the FV anticoagulant effect is directed towards.
There are other factors present in plasma that may affect the FV anticoagulant effect on FVa inactivation. Both prothrombin and FXa are known to protect FVa from proteolysis by APC [23, 24] . Recently, these interactions have been characterized in more detail [25, 26] . FXa inhibits cleavage of R506 by APC, which is partly reversed by protein S. However, cleavage at R306 is stimulated by FXa, which was shown to be additive to the stimulatory effect of protein S for cleavage at this site. Prothrombin protects both R306 and R506 from cleavage by APC, and here also protein S partially alleviates the protection. It is possible that FV further abrogates the protection by FXa and/or prothrombin, but further research will be required to determine if these factors play a role in the FV cofactor effect of APC-mediated FVa inactivation.
In conclusion, we have observed an anticoagulant effect of FV in a clotting assay that was sensitive to only FVa inactivation by APC. Therefore, we propose that FV acts as an anticoagulant cofactor for APC in the inactivation of both FVa and FVIIIa.
